Roche Holding AG (RHHBY)
OTCMKTS · Delayed Price · Currency is USD
56.75
-0.27 (-0.47%)
At close: Jan 30, 2026
Roche Holding AG Employees
Roche Holding AG had 103,249 employees as of December 31, 2024. The number of employees decreased by 356 or -0.34% compared to the previous year.
Employees
103,249
Change (1Y)
-356
Growth (1Y)
-0.34%
Revenue / Employee
$773,849
Profits / Employee
$157,320
Market Cap
387.90B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 103,249 | -356 | -0.34% |
| Dec 31, 2023 | 103,605 | -8 | -0.01% |
| Dec 31, 2022 | 103,613 | 2,693 | 2.67% |
| Dec 31, 2021 | 100,920 | -545 | -0.54% |
| Dec 31, 2020 | 101,465 | 3,730 | 3.82% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| American Oncology Network | 1,914 |
| Glass House Brands | 374 |
| Silence Therapeutics | 116 |
| Elite Pharmaceuticals | 68 |
| Northwest Biotherapeutics | 25 |
| CytoDyn | 13 |
| Tian'an Technology Group | 8 |
| OpGen | 1 |
Roche Holding AG News
- 2 days ago - Harbor Small Cap Growth Fund Q4 2025 Portfolio Performance - Seeking Alpha
- 2 days ago - Roche Holding AG (RHHBY) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 2 days ago - Roche Holding AG 2025 Q4 - Results - Earnings Call Presentation - Seeking Alpha
- 2 days ago - Roche Holding AG (RHHBF) (FY 2025) Earnings Call Highlights: Strong Pharma Growth and Strategic ... - GuruFocus
- 2 days ago - Full Year 2025 Roche Holding AG Earnings Call Transcript - GuruFocus
- 2 days ago - Roche's Full-Year Earnings: Solid, No Alarms - Obesity Promise Makes The Buy Case - Seeking Alpha
- 2 days ago - Roche Sees Steady 2026 Growth As Key Drugs Post Double-Digit Gains - Benzinga
- 2 days ago - How Roche Hopes To Go Toe-To-Toe With Eli Lilly, Novo Nordisk In Obesity - Investor's Business Daily